Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Indiana University logo

Indiana University

Status

Active, not recruiting

Conditions

Melanoma; Renal Cell Carcinoma

Treatments

Other: Blood collection for laboratory studies
Other: Data collection from medical record

Study type

Observational

Funder types

Other

Identifiers

NCT03728842
IUCRO-0042
1011003667 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

Full description

Spontaneous regression in patients with metastatic cancer is an incredibly rare event. It has been described after infection in cancer patients and also rarely in patients with renal cell cancer (usually after resection of the renal primary) and, less commonly, in patients with metastatic melanoma. Primary Objective To collect peripheral blood from patients with metastatic melanoma and renal cell cancer and spontaneous regression for studies of immune response and other studies. Secondary Objective To collect clinical data from subjects registered to this study. Clinical data collection will include demographics and cancer characteristics, history and treatment.

Enrollment

19 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

  • ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
  • Willingness to undergo phlebotomy for research blood samples

Exclusion Criteria

  • Concurrent disease or condition that would make the patient inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent

Trial design

19 participants in 1 patient group

Spontaneous regression
Description:
Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
Treatment:
Other: Data collection from medical record
Other: Blood collection for laboratory studies

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems